Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Sho-ichi Yamagishi
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Anatomy
Disorders
Living Beings
Sign-in to see full Profile
Network (preview)
96
Nakamura, Kazuo
85
Takeuchi, Masayoshi
83
Matsui, Takanori
64
Imaizumi, Tsutomu
40
Inoue, Hiroyoshi
33
Inagaki, Yosuke
30
Ueda, Seiji
25
Okuda, Seiya
22
Okamoto, Tamami
22
Amano, Shinjiro
17
Takenaka, Katsuhiko
15
Adachi, Hisashi
15
Kikuchi, Seiji
14
Fukami, Kei
14
Makita, Zenji
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Sho-ichi Yamagishi (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Fukami Ako; Adachi Hisashi; Yamagishi Sho-ichi; Matsui Takanori; Ueda Shin-ichiro; Nakamura Kazuo; Enomoto Mika; Otsuka Maki; Kumagae Shun-ichi; Nanjo Yasuki; Kumagai Eita; Esaki Eishi; Murayama Kyoko; Hirai Yuji; Imaizumi Tsutomu
Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population.
Metabolism: clinical and experimental 2009;58(12):1688-93.
-
2009: Nakamura Tsukasa; Sato Eiichi; Fujiwara Nobuharu; Kawagoe Yasuhiro; Suzuki Tsukasa; Ueda Yoshihiko; Yamada Shingo; Shoji Hisataka; Takeuchi Masayoshi; Ueda Seiji; Matsui Takanori; Adachi Hisashi; Okuda Seiya; Yamagishi Sho-ichi
Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock.
Pharmacological research : the official journal of the Italian Pharmacological Society 2009;60(6):515-8.
-
2009: Nakamura Tsukasa; Sato Eiichi; Fujiwara Nobuharu; Kawagoe Yasuhiro; Ueda Yoshihiko; Suzuki Tsukasa; Ueda Seiji; Adachi Hisashi; Okuda Seiya; Yamagishi Sho-ichi
Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner.
Pharmacological research : the official journal of the Italian Pharmacological Society 2009;60(6):525-8.
-
2009: Nakamura Tsukasa; Sato Eiichi; Fujiwara Nobuharu; Kawagoe Yasuhiro; Ueda Yoshihiko; Suzuki Tsukasa; Yamada Shingo; Takeuchi Masayoshi; Fukami Kei; Ueda Seiji; Adachi Hisashi; Matsui Takanori; Okuda Seiya; Yamagishi Sho-ichi
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
Metabolism: clinical and experimental 2009;58(11):1624-8.
-
2009: Yoshida Yumiko; Yamagishi Sho-Ichi; Matsui Takanori; Jinnouchi Yuko; Fukami Kei; Imaizumi Tsutomu; Yamakawa Ryoji
Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy.
Diabetes/metabolism research and reviews 2009;25(7):678-86.
-
2009: Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori
Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
Pharmacological research : the official journal of the Italian Pharmacological Society 2009;60(3):174-8.
-
2009: Yamagishi Sho-ichi; Adachi Hisashi; Matsui Takanori; Nakamura Kazuo; Enomoto Mika; Fukami Ako; Otsuka Maki; Kumagae Shun-ichi; Nanjo Yasuki; Imaizumi Tsutomu
Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population.
Clinical cardiology 2009;32(9):E29-32.
-
2009: Yamagishi Sho-ichi; Adachi Hisashi; Matsui Takanori; Nakamura Kazuo; Takeuchi Masayoshi; Enomoto Mika; Fukami Ako; Otsuka Maki; Kumagae Shun-ichi; Nanjo Yasuki; Ueda Shin-ichiro; Imaizumi Tsutomu
Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects.
Clinical cardiology 2009;32(9):E12-5.
-
2009: Nakamura Kazuo; Yamagishi Sho-ichi; Adachi Hisashi; Matsui Takanori; Kurita Yayoi; Inoue Hiroyoshi
Serum level of pigment epithelium derived factor (PEDF) is an independent determinant of resting heart rate in Japanese subjects.
International journal of cardiology 2009;136(2):245-7.
-
2009: Yoshida Tatsuhiro; Park Jin Soo; Yokosuka Kimiaki; Jimbo Kotaro; Yamada Kei; Sato Kimiaki; Takeuchi Masayoshi; Yamagishi Sho-Ichi; Nagata Kensei
Up-regulation in receptor for advanced glycation end-products in inflammatory circumstances in bovine coccygeal intervertebral disc specimens in vitro.
Spine 2009;34(15):1544-8.
-
2009: Matsui Takanori; Yamagishi Sho-ichi; Takeuchi Masayoshi; Ueda Seiji; Fukami Kei; Okuda Seiya
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
Biochemical and biophysical research communications 2009;385(2):269-72.
-
2009: Ueda Seiji; Yamagishi Sho-ichi; Matsumoto Yuriko; Kaida Yusuke; Fujimi-Hayashida Ayako; Koike Kiyomi; Tanaka Hideharu; Fukami Kei; Okuda Seiya
Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD).
Life sciences 2009;84(23-24):853-6.
-
2009: Fujimura Toshiko; Yamagishi Sho-ichi; Ueda Seiji; Fukami Kei; Shibata Ryo; Matsumoto Yuriko; Kaida Yusuke; Hayashida Ayako; Koike Kiyomi; Matsui Takanori; Nakamura Kei-ichiro; Okuda Seiya
Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009;24(5):1397-406.
-
2009: Takeuchi Masayoshi; Yamagishi Sho-ichi
Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease.
Journal of Alzheimer's disease : JAD 2009;16(4):845-58.
-
2009: Shibata Ryo; Ueda Seiji; Yamagishi Sho-Ichi; Kaida Yusuke; Matsumoto Yuriko; Fukami Kei; Hayashida Ayako; Matsuoka Hidehiro; Kato Seiya; Kimoto Masumi; Okuda Seiya
Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009;24(4):1162-9.
-
2009: Nakamura Kazuo; Adachi Hisashi; Matsui Takanori; Kurita Yayoi; Takeuchi Masayoshi; Yamagishi Sho-ichi
Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients.
Metabolism: clinical and experimental 2009;58(3):421-5.
-
2009: Yamagishi Sho-Ichi; Matsui Takanori; Takenaka Katsuhiko; Nakamura Kazuo; Takeuchi Masayoshi; Inoue Hiroyoshi
Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs).
Diabetes/metabolism research and reviews 2009;25(3):266-71.
-
2009: Yamagishi S; Matsui T; Nakamura K; Takenaka K
Administration of pigment epithelium-derived factor prolongs bleeding time by suppressing plasminogen activator inhibitor-1 activity and platelet aggregation in rats.
Clinical and experimental medicine 2009;9(1):73-6.
-
2009: Yamagishi Sho-ichi; Matsui Takanori; Ueda Seiji; Fukami Kei; Okuda Seiya
Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.
Current drug metabolism 2009;10(2):159-63.
-
2009: Shigetoh Yoshiyuki; Adachi Hisashi; Yamagishi Sho-ichi; Enomoto Mika; Fukami Ako; Otsuka Maki; Kumagae Shun-ichi; Furuki Kumiko; Nanjo Yasuki; Imaizumi Tsutomu
Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population.
American journal of hypertension 2009;22(2):151-5.
-
2009: Sato Takashi; Wu Xuegang; Shimogaito Noriko; Takino Jun-ichi; Yamagishi Sho-ichi; Takeuchi Masayoshi
Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys.
European journal of nutrition 2009;48(1):6-11.
-
2009: Nakamura Kazuo; Yamagishi Sho-Ichi; Adachi Hisashi; Kurita-Nakamura Yayoi; Matsui Takanori; Inoue Hiroyoshi
Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes.
Diabetes/metabolism research and reviews 2009;25(1):52-6.
-
2009: Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo
Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders.
Current pharmaceutical design 2009;15(9):1027-33.
-
2009: Nagano Makio; Fukami Kei; Yamagishi Sho-ichi; Ueda Seiji; Kaida Yusuke; Matsumoto Takafumi; Yoshimura Junko; Hazama Takuma; Takamiya Yoshimi; Kusumoto Takuo; Gohara Shojiro; Tanaka Hideharu; Adachi Hisashi; Okuda Seiya
Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease.
American journal of nephrology 2009;29(2):109-15.
-
2008: Yamagishi S; Matsui T; Nakamura K
Possible link of food-derived advanced glycation end products (AGEs) to the development of diabetes.
Medical hypotheses 2008;71(6):876-8.
-
2008: Yamagishi Sho-Ichi; Matsui Takanori; Nakamura Kazuo; Ueda So; Noda Yoshihiro; Imaizumi Tsutomu
Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications.
Current drug targets 2008;9(11):1025-9.
-
2008: Yamagishi S; Matsui T; Nakamura K
Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.
Medical hypotheses 2008;71(5):749-51.
-
2008: Yamagishi S-I; Matsui T; Nakamura K
Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2008;40(9):640-4.
-
2008: Yoshida T; Yamagishi S; Nakamura K; Matsui T; Imaizumi T; Takeuchi M; Koga H; Ueno T; Sata M
Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2008;40(9):620-5.
-
2008: Ueda Seiji; Matsumoto Yuriko; Kaida Yusuke; Okuda Seiya; Yamagishi Sho-Ichi
[Endothelial injury and CKD]
Nippon rinsho. Japanese journal of clinical medicine 2008;66(9):1634-8.
-
2008: Yamagishi Sho-ichi
Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA.
European heart journal 2008;29(15):1922.
-
2008: Yamagishi S; Matsui T; Nakamura K
Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers.
Medical hypotheses 2008;71(2):259-61.
-
2008: Yamagishi Sho-Ichi; Nakamura Kazuo; Matsui Takanori; Ueda Seiji; Fukami Kei; Okuda Seiya
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Expert opinion on investigational drugs 2008;17(7):983-96.
-
2008: Yamagishi Sho-ichi
Comment on: Thallas-Bonke et al. (2008) Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway: Diabetes 57:460-469, 2008.
Diabetes 2008;57(6):e13; author reply e14.
-
2008: Kitaichi Nobuyoshi; Shimizu Tadamichi; Yoshida Kazuhiko; Honda Ayumi; Yoshihisa Yoko; Kase Satoru; Ohgami Kazuhiro; Norisugi Osamu; Makino Teruhiko; Nishihira Jun; Yamagishi Sho-Ichi; Ohno Shigeaki
Macrophage migration inhibitory factor ameliorates UV-induced photokeratitis in mice.
Experimental eye research 2008;86(6):929-35.
-
2008: Nakamura Kazuo; Yamagishi Sho-ichi; Adachi Hisashi; Matsui Takanori; Kurita-Nakamura Yayoi; Takeuchi Masayoshi; Inoue Hiroyoshi; Imaizumi Tsutomu
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Microvascular research 2008;76(1):52-6.
-
2008: Yoshida T; Yamagishi S; Matsui T; Nakamura K; Ueno T; Takeuchi M; Sata M
Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation.
The Journal of international medical research 2008;36(2):237-43.
-
2008: Takenaka Katsuhiko; Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo; Jinnouchi Yuko; Yoshida Yumiko; Ueda Shin-ichiro; Katsuki Yoshio; Katsuda Yousuke; Imaizumi Tsutomu
Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes.
Atherosclerosis 2008;197(1):25-33.
-
2008: Nakamura Kazuo; Yamagishi Sho-ichi; Adachi Hisashi; Matsui Takanori; Kurita-Nakamura Yayoi; Takeuchi Masayoshi; Inoue Hiroyoshi; Imaizumi Tsutomu
Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
Diabetes/metabolism research and reviews 2008;24(2):109-14.
-
2008: Honda Ayumi; Abe Riichiro; Makino Teruhiko; Norisugi Osamu; Fujita Yasuyuki; Watanabe Hirokazu; Nishihira Jun; Iwakura Yoichiro; Yamagishi Sho-ichi; Shimizu Hiroshi; Shimizu Tadamichi
Interleukin-1beta and macrophage migration inhibitory factor (MIF) in dermal fibroblasts mediate UVA-induced matrix metalloproteinase-1 expression.
Journal of dermatological science 2008;49(1):63-72.
-
2008: Yoshida Y; Yamagishi S; Ueda S; Yoshimura K; Okuda S; Yamakawa R
Aqueous humor levels of asymmetric dimethylarginine (ADMA) are positively associated with monocyte chemoattractant protein-1 (MCP-1) in patients with uveitis.
The British journal of ophthalmology 2008;92(1):93-4.
-
2008: Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo; Inoue Hiroyoshi; Takeuchi Masayoshi; Ueda Seiji; Fukami Kei; Okuda Seiya; Imaizumi Tsutomu
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
Microvascular research 2008;75(1):130-4.
-
2008: Abe Riichiro; Fujita Yasuyuki; Yamagishi Sho-ichi; Shimizu Hiroshi
Pigment epithelium-derived factor prevents melanoma growth via angiogenesis inhibition.
Current pharmaceutical design 2008;14(36):3802-9.
-
2008: Yamagishi Sho-ichi; Ueda Seiji; Nakamura Kazuo; Matsui Takanori; Okuda Seiya
Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
Current pharmaceutical design 2008;14(25):2613-8.
-
2008: Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo; Takeuchi Masayoshi; Inoue Hiroyoshi
Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation.
Protein and peptide letters 2008;15(8):850-3.
-
2008: Unoki Hiroyuki; Yamagishi Sho-ichi
Advanced glycation end products and insulin resistance.
Current pharmaceutical design 2008;14(10):987-9.
-
2008: Takeuchi Masayoshi; Yamagishi Sho-ichi
Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Current pharmaceutical design 2008;14(10):973-8.
-
2008: Hyogo Hideyuki; Yamagishi Sho-ichi
Advanced glycation end products (AGEs) and their involvement in liver disease.
Current pharmaceutical design 2008;14(10):969-72.
-
2008: Yamagishi Sho-ichi; Ueda Seiji; Matsui Takanori; Nakamura Kazuo; Okuda Seiya
Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Current pharmaceutical design 2008;14(10):962-8.
-
2008: Fukami Kei; Yamagishi Sho-Ichi; Ueda Seiji; Okuda Seiya
Role of AGEs in diabetic nephropathy.
Current pharmaceutical design 2008;14(10):946-52.
-
2008: Abe Riichiro; Yamagishi Sho-ichi
AGE-RAGE system and carcinogenesis.
Current pharmaceutical design 2008;14(10):940-5.
-
2008: Yamagishi Sho-ichi
Advanced glycation end products (AGEs) and their receptor (RAGE) in health and disease.
Current pharmaceutical design 2008;14(10):939.
-
2008: Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori; Ueda So; Noda Yoshihiro; Imaizumi Tsutomu
Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
Cardiovascular therapeutics 2008;26(1):50-8.
-
2008: Iwamoto Keiko; Kanno Keishi; Hyogo Hideyuki; Yamagishi Sho-Ichi; Takeuchi Masayoshi; Tazuma Susumu; Chayama Kazuaki
Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.
Journal of gastroenterology 2008;43(4):298-304.
-
2008: Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori; Noda Yoshihiro; Imaizumi Tsutomu
Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Current pharmaceutical design 2008;14(5):487-95.
-
2008: Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori
Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.
Current medicinal chemistry 2008;15(2):172-7.
-
2008: Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo; Inoue Hiroyoshi; Takeuchi Masayoshi; Ueda Seiji; Okuda Seiya; Imaizumi Tsutomu
Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.
Ophthalmic research 2008;40(1):10-5.
-
2007: Ueda Seiji; Yamagishi Sho-Ichi; Kaida Yusuke; Okuda Seiya
Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.
Nephrology (Carlton, Vic.) 2007;12(6):582-90.
-
2007: Yamagishi S; Abe R; Jinnouchi Y; Matsui T; Imaizumi T; Inoue H
Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo.
The Journal of international medical research 2007;35(6):896-9.
-
2007: Yoshida Y; Yamagishi S; Ueda S; Yoshimura K; Okuda S; Yamakawa R
Aqueous humour levels of asymmetric dimethylarginine (ADMA) are correlated with pigment epithelium-derived factor (PEDF) in patients with uveitis.
The Journal of international medical research 2007;35(6):892-5.
-
2007: Matsui T; Yamagishi S; Nakamura K; Inoue H
Bay w 9798, a dihydropyridine structurally related to nifedipine with no calcium channel-blocking properties, inhibits tumour necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
The Journal of international medical research 2007;35(6):886-91.
-
2007: Yamagishi S; Adachi H; Takeuchi M; Enomoto M; Furuki K; Matsui T; Nakamura K; Imaizumi T
Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2007;39(11):845-8.
-
2007: Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo
Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Current drug targets 2007;8(10):1138-43.
-
2007: Ihara Yoshiko; Egashira Kensuke; Nakano Kaku; Ohtani Kisho; Kubo Mitsuki; Koga Jun-ichiro; Iwai Masaru; Horiuchi Masatsugu; Gang Zhao; Yamagishi Sho-ichi; Sunagawa Kenji
Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Journal of molecular and cellular cardiology 2007;43(4):455-64.
-
2007: Jinnouchi Yuko; Yamagishi Sho-ichi; Matsui Takanori; Takenaka Katsuhiko; Yoshida Yumiko; Nakamura Kazuo; Ueda Shin-ichiro; Imaizumi Tsutomu
Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice.
Brain research 2007;1167():92-100.
-
2007: Yoshida Yumiko; Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo; Imaizumi Tsutomu; Yoshimura Koichi; Yamakawa Ryoji
Positive correlation of pigment epithelium-derived factor and total antioxidant capacity in aqueous humour of patients with uveitis and proliferative diabetic retinopathy.
The British journal of ophthalmology 2007;91(9):1133-4.
-
2007: Yamagishi Sho-Ichi; Nakamura Kazuo; Matsui Takanori
Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
Current molecular medicine 2007;7(5):463-9.
-
2007: Yamagishi Sho-ichi; Fukami Kei; Ueda Seiji; Okuda Seiya
Molecular mechanisms of diabetic nephropathy and its therapeutic intervention.
Current drug targets 2007;8(8):952-9.
-
2007: Matsui T; Yamagishi S; Ueda S; Nakamura K; Imaizumi T; Takeuchi M; Inoue H
Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.
The Journal of international medical research 2007;35(4):482-9.
-
2007: Yamagishi Sho-Ichi; Matsui Takanori; Ueda Shin-Ichiro; Nakamura Kazuo; Imaizumi Tsutomu
Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes.
Cardiovascular & hematological agents in medicinal chemistry 2007;5(3):236-40.
-
2007: Hyogo Hideyuki; Yamagishi Sho-ichi; Iwamoto Keiko; Arihiro Koji; Takeuchi Masayoshi; Sato Takashi; Ochi Hidenori; Nonaka Michihiro; Nabeshima Yoshitaka; Inoue Motoki; Ishitobi Tomokazu; Chayama Kazuaki; Tazuma Susumu
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis.
Journal of gastroenterology and hepatology 2007;22(7):1112-9.
-
2007: Higashimoto Yuichiro; Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori; Takeuchi Masayoshi; Noguchi Masato; Inoue Hiroyoshi
In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes.
Microvascular research 2007;74(1):65-9.
-
2007: Yokoi Masahiko; Yamagishi Sho-ichi; Saito Akari; Yoshida Yumiko; Matsui Takanori; Saito Wataru; Hirose Shigeki; Ohgami Kazuhiro; Kase Manabu; Ohno Shigeaki
Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy.
The British journal of ophthalmology 2007;91(7):885-7.
-
2007: Nakamura Kazuo; Yamagishi Sho-ichi; Adachi Hisashi; Kurita-Nakamura Yayoi; Matsui Takanori; Yoshida Takafumi; Sato Akira; Imaizumi Tsutomu
Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.
Diabetes/metabolism research and reviews 2007;23(5):368-71.
-
2007: Ueda Seiji; Yamagishi Sho-ichi; Matsumoto Yuriko; Fukami Kei; Okuda Seiya
Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
Clinical and experimental nephrology 2007;11(2):115-21.
-
2007: Abe Riichiro; Fujita Yasuyuki; Yamagishi Sho-ichi
Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma.
Mini reviews in medicinal chemistry 2007;7(6):649-61.
-
2007: Fukami K; Yamagishi S; Ueda S; Okuda S
Novel therapeutic targets for diabetic nephropathy.
Endocrine, metabolic & immune disorders drug targets 2007;7(2):83-92.
-
2007: Nakamura Kazuo; Yamagishi Sho-ichi; Matsui Takanori; Yoshida Takafumi; Takenaka Katsuhiko; Jinnouchi Yuko; Yoshida Yumiko; Ueda Shin-ichiro; Adachi Hisashi; Imaizumi Tsutomu
Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation.
The American journal of pathology 2007;170(6):2159-70.
-
2007: Yamagishi Sho-ichi; Imaizumi Tsutomu
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(6):e32; author reply e33-4.
-
2007: Haramaki Nobuya; Ikeda Hisao; Takenaka Katsuhiko; Katoh Atsushi; Sugano Ryo; Yamagishi Sho-ichi; Matsuoka Hidehiro; Imaizumi Tsutomu
Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(6):1471-7.
-
2007: Yoshida Yumiko; Yamagishi Sho-Ichi; Matsui Takanori; Nakamura Kazuo; Imaizumi Tsutomu; Yoshimura Koichi; Yamakawa Ryoji
Positive correlation between pigment epithelium-derived factor and monocyte chemoattractant protein-1 levels in the aqueous humour of patients with uveitis.
The British journal of ophthalmology 2007;91(6):737-8.
-
2007: Nakamura K; Yamagishi S; Yoshida T; Matsui T; Imaizumi T; Inoue H; Sata M
Hydrogen peroxide stimulates pigment epithelium-derived factor gene and protein expression in the human hepatocyte cell line OUMS-29.
The Journal of international medical research 2007;35(3):427-32.
-
2007: Yokosuka Kimiaki; Park Jin Soo; Jimbo Kotaro; Yoshida Tatuhiro; Yamada Kei; Sato Kimiaki; Takeuchi Masayoshi; Yamagishi Sho-ichi; Nagata Kensei
Immunohistochemical demonstration of advanced glycation end products and the effects of advanced glycation end products in ossified ligament tissues in vitro.
Spine 2007;32(11):E337-9.
-
2007: Matsumoto Yuriko; Ueda Seiji; Yamagishi Sho-ichi; Matsuguma Kyoko; Shibata Ryo; Fukami Kei; Matsuoka Hidehiro; Imaizumi Tsutomu; Okuda Seiya
Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
Journal of the American Society of Nephrology : JASN 2007;18(5):1525-33.
-
2007: Unoki Hiroyuki; Bujo Hideaki; Yamagishi Sho-ichi; Takeuchi Masayoshi; Imaizumi Tsutomu; Saito Yasushi
Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes.
Diabetes research and clinical practice 2007;76(2):236-44.
-
2007: Yamagishi Sho-ichi; Matsuoka Hidehiro; Kitano Soichi; Hibi Nozomu; Jinnouchi Yuko; Umei Hidekazu; Iida Shuji; Takenaka Katsuhiko; Matsui Takanori; Nakamura Kazuo; Imaizumi Tsutomu
Elevated circulating oxidized LDL levels in Japanese subjects with the metabolic syndrome.
International journal of cardiology 2007;118(2):270-2.
-
2007: Tahara Nobuhiro; Kai Hisashi; Yamagishi Sho-ichi; Mizoguchi Minori; Nakaura Hiroyuki; Ishibashi Masatoshi; Kaida Hayato; Baba Kenkichi; Hayabuchi Naofumi; Imaizumi Tsutomu
Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome.
Journal of the American College of Cardiology 2007;49(14):1533-9.
-
2007: Kaneyuki Utako; Ueda Seiji; Yamagishi Sho-ichi; Kato Seiya; Fujimura Toshiko; Shibata Ryo; Hayashida Ayako; Yoshimura Junko; Kojiro Masamichi; Oshima Koichi; Okuda Seiya
Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation.
Vascular pharmacology 2007;46(4):286-92.
-
2007: Nakamura Kazuo; Yamagishi Sho-ichi; Adachi Hisashi; Kurita-Nakamura Yayoi; Matsui Takanori; Yoshida Takafumi; Imaizumi Tsutomu
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
Molecular medicine (Cambridge, Mass.) 2007;13(3-4):185-9.
-
2007: Yamagishi S-I; Nakamura K; Matsui T; Yoshida T; Takeuchi M; Imaizumi T
Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2007;39(3):233-5.
-
2007: Yokoi Masahiko; Yamagishi Sho-ichi; Takeuchi Masayoshi; Matsui Takanori; Yoshida Yumiko; Ohgami Kazuhiro; Amano-Okamoto Tamami; Ohno Shigeaki
Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation.
The British journal of ophthalmology 2007;91(3):397-8.
-
2007: Yoshida Yumiko; Yamagishi Sho-Ichi; Matsui Takanori; Nakamura Kazuo; Imaizumi Tsutomu; Yoshimura Koichi; Yamakawa Ryoji
Increased levels of pigment epithelium-derived factor in aqueous humor of patients with uveitis.
The British journal of ophthalmology 2007;91(2):149-50.
-
2007: Matsui T; Yamagishi S; Nakamura K; Inoue H; Takeuchi M
Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells.
The Journal of international medical research 2007;35(1):107-12.
-
2007: Yamagishi Sho-ichi; Ueda Seiji; Matsui Takanori; Nakamura Kazuo; Imaizumi Tsutomu; Takeuchi Masayoshi; Okuda Seiya
Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties.
Protein and peptide letters 2007;14(8):832-5.
-
2007: Yamagishi Sho-ichi; Ueda Seiji; Okuda Seiya
Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders.
Current pharmaceutical design 2007;13(27):2832-6.
-
2007: Takeuchi Masayoshi; Sato Takashi; Takino Jun-ichi; Kobayashi Yuka; Furuno Satomi; Kikuchi Seiji; Yamagishi Sho-ichi
Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease.
Medical hypotheses 2007;69(6):1358-66.
-
2007: Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo; Imaizumi Tsutomu
Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties.
Protein and peptide letters 2007;14(6):615-7.
-
2007: Yamagishi S; Ueda S; Okuda S
A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Medical hypotheses 2007;69(4):922-4.
-
2007: Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2007;69(3):666-8.
-
2007: Yamagishi S; Nakamura K; Matsui T; Inoue H
A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2007;69(2):338-40.
-
2007: Yamagishi Sho-Ichi; Matsui Takanori; Nakamura Kazuo; Yoshida Takafumi; Takeuchi Masayoshi; Inoue Hiroyoshi; Yoshida Yumiko; Imaizumi Tsutomu
Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats.
Ophthalmic research 2007;39(2):92-7.
-
2007: Yamagishi S; Matsui T; Nakamura K
Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
Medical hypotheses 2007;68(5):1096-8.
-
2007: Yamagishi S; Nakamura K
Revival of nifedipine, a dihydropyridine-based calcium blocker.
Medical hypotheses 2007;68(3):565-7.
-
2006: Yoshida T; Yamagishi S; Nakamura K; Matsui T; Imaizumi T; Takeuchi M; Koga H; Ueno T; Sata M
Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation.
Diabetologia 2006;49(12):3094-9.
-
2006: Matsui T; Yamagishi S; Nakamura K; Inoue H
Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.
The Journal of international medical research 2006;34(6):671-5.
-
2006: Yokosuka Kimiaki; Park Jin Soo; Jimbo Kotaro; Yamada Kei; Sato Kimiaki; Tsuru Michiyo; Takeuchi Masayoshi; Yamagishi Sho-Ichi; Nagata Kensei
Advanced glycation end-products downregulating intervertebral disc cell production of proteoglycans in vitro.
Journal of neurosurgery. Spine 2006;5(4):324-9.
-
2006: Motomiya Yoshihiro; Yamagishi Sho-Ichi; Adachi Hisashi; Abe Akio
Increased serum concentrations of pigment epithelium-derived factor in patients with end-stage renal disease.
Clinical chemistry 2006;52(10):1970-1.
-
2006: Yoshida Takafumi; Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori; Imaizumi Tsutomu; Inoue Hiroyoshi; Ueno Takato; Sata Michio
Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation.
Life sciences 2006;79(21):1981-7.
-
2006: Yamagishi Sho-ichi; Adachi Hisashi; Nakamura Kazuo; Matsui Takanori; Jinnouchi Yuko; Takenaka Katsuhiko; Takeuchi Masayoshi; Enomoto Mika; Furuki Kumiko; Hino Asuka; Shigeto Yoshiyuki; Imaizumi Tsutomu
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Metabolism: clinical and experimental 2006;55(9):1227-31.
-
2006: Niiya Yoshimasa; Abumiya Takeo; Shichinohe Hideo; Kuroda Satoshi; Kikuchi Seiji; Ieko Masahiro; Yamagishi Sho-ichi; Takeuchi Masayoshi; Sato Takashi; Iwasaki Yoshinobu
Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species.
Brain research 2006;1108(1):179-87.
-
2006: Yamagishi S -I; Kikuchi S; Nakamura K; Matsui T; Makino T; Norisugi O; Shimizu T; Inoue H; Imaizumi T
Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2006;38(8):546-8.
-
2006: Matsuguma Kyoko; Ueda Seiji; Yamagishi Sho-ichi; Matsumoto Yuriko; Kaneyuki Utako; Shibata Ryo; Fujimura Toshiko; Matsuoka Hidehiro; Kimoto Masumi; Kato Seiya; Imaizumi Tsutomu; Okuda Seiya
Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
Journal of the American Society of Nephrology : JASN 2006;17(8):2176-83.
-
2006: Ueda Seiji; Yamagishi Sho-ichi; Takeuchi Masayoshi; Kohno Keisuke; Shibata Ryo; Matsumoto Yuriko; Kaneyuki Utako; Fujimura Toshiko; Hayashida Ayako; Okuda Seiya
Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure.
Molecular medicine (Cambridge, Mass.) 2006;12(7-8):180-4.
-
2006: Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo; Takeuchi Masayoshi; Imaizumi Tsutomu
Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis.
Microvascular research 2006;72(1-2):86-90.
-
2006: Enomoto Mika; Adachi Hisashi; Yamagishi Sho-ichi; Takeuchi Masayoshi; Furuki Kumiko; Hino Asuka; Hiratsuka Akiko; Takajo Yoshinori; Imaizumi Tsutomu
Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans.
Metabolism: clinical and experimental 2006;55(7):912-7.
-
2006: Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori; Inagaki Yosuke; Takenaka Katsuhiko; Jinnouchi Yuko; Yoshida Yumiko; Matsuura Tetsuro; Narama Isao; Motomiya Yoshihiro; Takeuchi Masayoshi; Inoue Hiroyoshi; Yoshimura Akihiko; Bucala Richard; Imaizumi Tsutomu
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression.
The Journal of biological chemistry 2006;281(29):20213-20.
-
2006: Sato Takashi; Shimogaito Noriko; Wu Xuegang; Kikuchi Seiji; Yamagishi Sho-ichi; Takeuchi Masayoshi
Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease.
American journal of Alzheimer's disease and other dementias 2006;21(3):197-208.
-
2006: Yamagishi Sho-Ichi; Adachi Hisashi; Abe Akio; Yashiro Takako; Enomoto Mika; Furuki Kumiko; Hino Asuka; Jinnouchi Yuko; Takenaka Katsuhiko; Matsui Takanori; Nakamura Kazuo; Imaizumi Tsutomu
Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome.
The Journal of clinical endocrinology and metabolism 2006;91(6):2447-50.
-
2006: Yamagishi Sho-ichi; Kikuchi Seiji; Nakamura Kazuo; Matsui Takanori; Takeuchi Masayoshi; Inoue Hiroyoshi
Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2.
Medicinal chemistry (Shariqah (United Arab Emirates)) 2006;2(3):265-9.
-
2006: Kato Toru; Inoue Teruo; Yamagishi Sho-ichi; Morooka Toshifumi; Okimoto Takao; Node Koichi
Low-density lipoprotein subfractions and the prevalence of silent lacunar infarction in subjects with essential hypertension.
Hypertension research : official journal of the Japanese Society of Hypertension 2006;29(5):303-7.
-
2006: Sato Takashi; Iwaki Mina; Shimogaito Noriko; Wu Xuegang; Yamagishi Sho-Ichi; Takeuchi Masayoshi
TAGE (toxic AGEs) theory in diabetic complications.
Current molecular medicine 2006;6(3):351-8.
-
2006: Yoshida Takafumi; Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori; Imaizumi Tsutomu; Takeuchi Masayoshi; Ueno Takato; Sata Michio
Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation.
FEBS letters 2006;580(11):2788-96.
-
2006: Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo; Yoshida Takafumi; Shimizu Kyoko; Takegami Yoshiaki; Shimizu Tadamichi; Inoue Hiroyoshi; Imaizumi Tsutomu
Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties.
Microvascular research 2006;71(3):222-6.
-
2006: Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori
Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Current drug discovery technologies 2006;3(1):83-8.
-
2006: Yamagishi Sho-ichi; Nakamura Kazuo; Matsui Takanori; Takenaka Katsuhiko; Jinnouchi Yuko; Imaizumi Tsutomu
Cardiovascular disease in diabetes.
Mini reviews in medicinal chemistry 2006;6(3):313-8.
-
2006: Takenaka Katsuhiko; Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo; Imaizumi Tsutomu
Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes.
Current neurovascular research 2006;3(1):73-7.
-
2006: Yamagishi Sho-ichi; Nakamura Kazuo
Telmisartan, its potential therapeutic implications in cardiometabolic disorders.
Recent patents on cardiovascular drug discovery 2006;1(1):79-83.
-
2006: Yamagishi Sho-ichi; Matsui Takanori; Nakamura Kazuo
Atorvastatin and diabetic vascular complications.
Current pharmaceutical design 2006;12(12):1549-54.
-
2006: Yamagishi Sho-ichi; Nakamura Kazuo; Takenaka Katsuhiko; Matsui Takanori; Inoue Hiroyoshi
Pleiotropic effects of nifedipine on atherosclerosis.
Current pharmaceutical design 2006;12(12):1543-7.
-
2006: Yamagishi S; Nakamura K; Matsui T; Takeuchi Masayoshi
Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.
Medical hypotheses 2006;66(2):273-5.
-
2006: Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Medical hypotheses 2006;66(4):844-6.
-
2006: Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Medical hypotheses 2006;66(5):1019-21.
-
2006: Yamagishi S; Matsui T; Sato T; Takeuchi M
Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Medical hypotheses 2006;66(3):609-11.
-
2006: Yamagishi S; Takenaka K; Inoue H
Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Medical hypotheses 2006;66(1):118-20.
-
2005: Nakamura Kazuo; Yamagishi Sho-Ichi; Nakamura Yayoi; Takenaka Katsuhiko; Matsui Takanori; Jinnouchi Yuko; Imaizumi Tsutomu
Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.
Microvascular research 2005;70(3):137-41.
-
2005: Takenaka Katsuhiko; Yamagishi Sho-Ichi; Jinnouchi Yuko; Nakamura Kazuo; Matsui Takanori; Imaizumi Tsutomu
Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells.
Life sciences 2005;77(25):3231-41.
-
2005: Kume Shinichiro; Kato Seiya; Yamagishi Sho-ichi; Inagaki Yosuke; Ueda Seiji; Arima Nobuyuki; Okawa Takahiro; Kojiro Masamichi; Nagata Kensei
Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2005;20(9):1647-58.
-
2005: Yamagishi Sho-Ichi; Takeuchi Masayoshi; Matsui Takanori; Nakamura Kazuo; Imaizumi Tsutomu; Inoue Hiroyoshi
Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression.
FEBS letters 2005;579(20):4265-70.
-
2005: Yamagishi Sho-ichi; Imaizumi Tsutomu
[Molecular mechanism of diabetic retinopathy: role of advanced glycation end products(AGEs) and their receptor (RAGE) in the pathogenesis of diabetic retinopathy]
Nippon Ganka Gakkai zasshi 2005;109(6):338-45.
-
2005: Yamagishi Sho-ichi; Imaizumi Tsutomu
[Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors]
Nippon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 6():136-8.
-
2005: Yokoi M; Yamagishi S-I; Takeuchi M; Ohgami K; Okamoto T; Saito W; Muramatsu M; Imaizumi T; Ohno S
Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy.
The British journal of ophthalmology 2005;89(6):673-5.
-
2005: Yamagishi Sho-Ichi; Nakamura Kazuo; Ueda Seiji; Kato Seiya; Imaizumi Tsutomu
Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF.
Cell and tissue research 2005;320(3):437-45.
-
2005: Yamagishi Sho-Ichi; Nakamura Kazuo; Takenaka Katsuhiko; Matsui Takanori; Jinnouchi Yuko; Imaizumi Tsutomu
Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B.
Microvascular research 2005;69(3):128-34.
-
2005: Hiratsuka Akiko; Adachi Hisashi; Fujiura Yoshihisa; Yamagishi Sho-Ichi; Hirai Yuji; Enomoto Mika; Satoh Akira; Hino Asuka; Furuki Kumiko; Imaizumi Tsutomu
Strong association between serum hepatocyte growth factor and metabolic syndrome.
The Journal of clinical endocrinology and metabolism 2005;90(5):2927-31.
-
2005: Yamagishi Sho-ichi; Nakamura Kazuo; Imaizumi Tsutomu
Advanced glycation end products (AGEs) and diabetic vascular complications.
Current diabetes reviews 2005;1(1):93-106.
-
2005: Amano Shinjiro; Yamagishi Sho-Ichi; Inagaki Yosuke; Nakamura Kazuo; Takeuchi Masayoshi; Inoue Hiroyoshi; Imaizumi Tsutomu
Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes.
Microvascular research 2005;69(1-2):45-55.
-
2005: Yamagishi S; Matsui T; Nakamura K; Inoue H
Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy.
International journal of tissue reactions 2005;27(4):197-202.
-
2005: Yamagishi S; Matsui T; Nakamura K; Takeuchi M
Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
International journal of tissue reactions 2005;27(4):189-95.
-
2005: Yamagishi S; Matsui T; Inoue H
Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells.
Drugs under experimental and clinical research 2005;31(5-6):227-32.
-
2005: Yamagishi S; Kikuchi S; Takenaka K; Takeuchi M
Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells.
Drugs under experimental and clinical research 2005;31(5-6):221-6.
-
2005: Matsui T; Yamagishi S; Nakamura K; Kikuchi S; Inoue H
Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
Drugs under experimental and clinical research 2005;31(5-6):215-9.
-
2005: Yamagishi S; Takeuchi M; Inoue H
Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats.
International journal of tissue reactions 2005;27(3):137-43.
-
2005: Yamagishi S; Imaizumi T
Pericyte biology and diseases.
International journal of tissue reactions 2005;27(3):125-35.
-
2005: Nakamura K; Yamagishi S; Matsui T; Inoue H
Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Drugs under experimental and clinical research 2005;31(4):155-9.
-
2005: Yamagishi S; Nakamura K; Inoue H
Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Medical hypotheses 2005;65(6):1013-5.
-
2005: Yamagishi S; Takeuchi M
Atheroprotective properties of nifedipine.
International journal of tissue reactions 2005;27(2):63-7.
-
2005: Yamagishi S; Nakamura K; Jinnouchi Y; Takenaka K; Imaizumi T
Molecular mechanisms for vascular injury in the metabolic syndrome.
Drugs under experimental and clinical research 2005;31(3):123-9.
-
2005: Yamagishi Sho-ichi; Imaizumi Tsutomu
Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.
Current pharmaceutical design 2005;11(18):2279-99.
-
2005: Yamagishi S; Nakamura K; Inoue H
Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2005;65(5):953-5.
-
2005: Yamagishi S; Takeuchi M; Inoue H
Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats.
Drugs under experimental and clinical research 2005;31(2):45-51.
-
2005: Yamagishi S; Nakamura K; Takeuchi M
Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2005;65(2):392-4.
-
2005: Yamagishi S; Nakamura K; Inoue H
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Medical hypotheses 2005;65(2):377-9.
-
2005: Yamagishi S; Takeuchi M
Nifedipine inhibits tumor necrosis factor-alpha-induced upregulation of monocyte chemoattractant protein-1 mRNA levels by suppressing CD40 expression in endothelial cells.
Drugs under experimental and clinical research 2005;31(1):13-7.
-
2005: Nakamura K; Yamagishi S; Inoue H
Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Medical hypotheses 2005;65(1):155-7.
-
2005: Yamagishi S; Nakamura K; Takeuchi M
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Medical hypotheses 2005;65(1):152-4.
-
2005: Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
Medical hypotheses 2005;64(6):1208-10.
-
2005: Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Medical hypotheses 2005;64(6):1205-7.
-
2005: Yamagishi S; Nakamura K; Inoue H; Takeuchi M
Met72Thr polymorphism of pigment epithelium-derived factor gene and susceptibility to age-related macular degeneration.
Medical hypotheses 2005;64(6):1202-4.
-
2005: Yamagishi S; Takeuchi M
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Medical hypotheses 2005;64(3):476-8.
-
2004: Yamagishi Sho-ichi; Abe Riichiro; Inagaki Yosuke; Nakamura Kazuo; Sugawara Hiroshi; Inokuma Daisuke; Nakamura Hideki; Shimizu Tadamichi; Takeuchi Masayoshi; Yoshimura Akihiko; Bucala Richard; Shimizu Hiroshi; Imaizumi Tsutomu
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.
The American journal of pathology 2004;165(6):1865-74.
-
2004: Fukami Kei; Ueda Seiji; Yamagishi Sho-ichi; Kato Seiya; Inagaki Yosuke; Takeuchi Masayoshi; Motomiya Yoshihiro; Bucala Richard; Iida Shuji; Tamaki Kiyoshi; Imaizumi Tsutomu; Cooper Mark E; Okuda Seiya
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction.
Kidney international 2004;66(6):2137-47.
-
2004: Kaji Toshiyuki; Sakurai Shigeru; Yamamoto Chika; Fujiwara Yasuyuki; Yamagishi Sho-ichi; Yamamoto Hiroshi; Kinsella Michael G; Wight Thomas N
Characterization of chondroitin/dermatan sulfate proteoglycans synthesized by bovine retinal pericytes in culture.
Biological & pharmaceutical bulletin 2004;27(11):1763-8.
-
2004: Choei Hiroshi; Sasaki Nobuyuki; Takeuchi Masayoshi; Yoshida Taku; Ukai Wataru; Yamagishi Sho-Ichi; Kikuchi Seiji; Saito Toshikazu
Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease.
Acta neuropathologica 2004;108(3):189-93.
-
2004: Yamagishi Sho-Ichi; Inagaki Yosuke; Nakamura Kazuo; Abe Riichiro; Shimizu Tadamichi; Yoshimura Akihiko; Imaizumi Tsutomu
Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation.
Journal of molecular and cellular cardiology 2004;37(2):497-506.
-
2004: Yamagishi Sho-ichi; Inagaki Yosuke; Nakamura Kazuo; Imaizumi Tsutomu
Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties.
Journal of cardiovascular pharmacology 2004;43(5):724-30.
-
2004: Abe Riichiro; Shimizu Tadamichi; Yamagishi Sho-Ichi; Shibaki Akihiko; Amano Shinjiro; Inagaki Yosuke; Watanabe Hirokazu; Sugawara Hiroshi; Nakamura Hideki; Takeuchi Masayoshi; Imaizumi Tsutomu; Shimizu Hiroshi
Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo.
The American journal of pathology 2004;164(4):1225-32.
-
2004: Takeuchi Masayoshi; Kikuchi Seiji; Sasaki Nobuyuki; Suzuki Takako; Watai Takayuki; Iwaki Mina; Bucala Richard; Yamagishi Sho-ichi
Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease.
Current Alzheimer research 2004;1(1):39-46.
-
2004: Abe Riichiro; Shimizu Tadamichi; Sugawara Hiroshi; Watanabe Hirokazu; Nakamura Hideki; Choei Hiroshi; Sasaki Nobuyuki; Yamagishi Sho-ichi; Takeuchi Masayoshi; Shimizu Hiroshi
Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions.
The Journal of investigative dermatology 2004;122(2):461-7.
-
2004: Miura Junnosuke; Uchigata Yasuko; Yamamoto Yasuhiko; Takeuchi Masayoshi; Sakurai Sigeru; Watanabe Takuo; Yonekura Hideto; Yamagishi Sho-Ichi; Makita Zenji; Sato Akiko; Omori Yasue; Yamamoto Hiroshi; Iwamoto Yasuhiko
AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes.
Journal of diabetes and its complications 2004;18(1):53-9.
-
2004: Yamagishi S; Nakamura K; Takeuchi M; Imaizumi T
Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention.
International journal of clinical pharmacology research 2004;24(4):129-34.
-
2004: Takeuchi M; Yamagishi S; Iwaki M; Nakamura K; Imaizumi T
Advanced glycation end product (age) inhibitors and their therapeutic implications in diseases.
International journal of clinical pharmacology research 2004;24(2-3):95-101.
-
2004: Yamagishi S; Takeuchi M
Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation.
Drugs under experimental and clinical research 2004;30(4):169-75.
-
2004: Yamagishi S; Takeuchi M
Nifedipine inhibits tumor necrosis factor-alpha-induced leukocyte adhesion to endothelial cells by suppressing vascular cell adhesion molecule-1 (VCAM-1) expression.
Drugs under experimental and clinical research 2004;30(4):163-8.
-
2004: Takeuchi M; Yamagishi S
Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo.
Medical hypotheses 2004;63(3):453-5.
-
2004: Takeuchi M; Yamagishi S
TAGE (toxic AGEs) hypothesis in various chronic diseases.
Medical hypotheses 2004;63(3):449-52.
-
2004: Yamagishi S; Takeuchi M
Inhibition of protein kinase C might be harmful to diabetic retinopathy.
Medical hypotheses 2004;63(1):135-7.
-
2004: Yamagishi S; Inagaki Y; Takeuchi M; Sasaki N
Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease?
Medical hypotheses 2004;63(1):115-7.
-
2003: Takeuchi Masayoshi; Watai Takayuki; Sasaki Nobuyuki; Choei Hiroshi; Iwaki Mina; Ashizawa Takeshi; Inagaki Yosuke; Yamagishi Sho-Ichi; Kikuchi Seiji; Riederer Peter; Saito Toshikazu; Bucala Richard; Kameda Yukihiko
Neurotoxicity of acetaldehyde-derived advanced glycation end products for cultured cortical neurons.
Journal of neuropathology and experimental neurology 2003;62(5):486-96.
-
2003: Yamagishi Sho-ichi; Amano Shinjiro; Inagaki Yosuke; Okamoto Tamami; Takeuchi Masayoshi; Inoue Hiroyoshi
Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties.
Microvascular research 2003;65(3):186-90.
-
2003: Amano S; Yamagishi S; Koda Y; Tsuneoka M; Soejima M; Okamoto T; Inagaki Y; Yamada K; Kimura H
Polymorphisms of sorbitol dehydrogenase (SDH) gene and susceptibility to diabetic retinopathy.
Medical hypotheses 2003;60(4):550-1.
-
2003: Yamagishi S; Okamoto T; Amano S; Inagaki Y
Can we identify novel angiogenesis inhibitors from cultured embryonic cells?
Medical hypotheses 2003;60(3):389-90.
-
2003: Yamagishi Sho-Ichi; Inagaki Yosuke; Okamoto Tamami; Amano Shinjiro; Koga Kohachiro; Takeuchi Masayoshi
Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells.
Kidney international 2003;63(2):464-73.
-
2003: Inagaki Y; Yamagishi S; Okamoto T; Takeuchi M; Amano S
Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation.
Diabetologia 2003;46(2):284-7.
-
2003: Miura Junnosuke; Yamagishi Sho ichi; Uchigata Yasuko; Takeuchi Masayoshi; Yamamoto Hiroshi; Makita Zenji; Iwamoto Yasuhiko
Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
Journal of diabetes and its complications 2003;17(1):16-21.
-
2003: Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
International journal of clinical pharmacology research 2003;23(4):129-34.
-
2003: Yamagishi S; Inagaki Y; Kikuchi S
Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation.
Drugs under experimental and clinical research 2003;29(4):147-52.
-
2003: Yamagishi S; Inagaki Y; Abe R; Kikuchi S; Sasaki N; Takeuchi M
Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha.
Drugs under experimental and clinical research 2003;29(4):141-5.
-
2003: Amano S; Yamagishi S; Inagaki Y; Okamoto T
Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation.
International journal of tissue reactions 2003;25(2):51-5.
-
2003: Yamagishi S; Amano S; Inagaki Y; Okamoto T; Inoue H; Takeuchi M; Choei H; Sasaki N; Kikuchi S
Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation.
Drugs under experimental and clinical research 2003;29(2):75-80.
-
2002: Okamoto Tamami; Yamagishi Sho-ichi; Inagaki Yosuke; Amano Shinjiro; Koga Kohachiro; Abe Riichiro; Takeuchi Masayoshi; Ohno Shigeaki; Yoshimura Akihiko; Makita Zenji
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2002;16(14):1928-30.
-
2002: Amano Shinjiro; Yamagishi Sho ichi; Kato Noriaki; Inagaki Yosuke; Okamoto Tamami; Makino Mitsuhiro; Taniko Kaori; Hirooka Hiroko; Jomori Takahito; Takeuchi Masayoshi
Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes.
Biochemical and biophysical research communications 2002;299(2):183-8.
-
2002: Koga Kohachiro; Yamagishi Sho-ichi; Takeuchi Masayoshi; Inagaki Yosuke; Amano Shinjiro; Okamoto Tamami; Saga Tsuyoshi; Makita Zenji; Yoshizuka Mitsuaki
CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Molecular medicine (Cambridge, Mass.) 2002;8(10):591-9.
-
2002: Inagaki Yosuke; Yamagishi Sho-ichi; Amano Shinjiro; Okamoto Tamami; Koga Kohachiro; Makita Zenji
Interferon-gamma-induced apoptosis and activation of THP-1 macrophages.
Life sciences 2002;71(21):2499-508.
-
2002: Yamagishi Sho-ichi; Amano Shinjiro; Inagaki Yosuke; Okamoto Tamami; Takeuchi Masayoshi; Makita Zenji
Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes.
Molecular medicine (Cambridge, Mass.) 2002;8(9):546-50.
-
2002: Takeuchi Masayoshi; Yamagishi Sho-ichi; Makita Zenji
[OPB-9195]
Nippon rinsho. Japanese journal of clinical medicine 2002;60 Suppl 9():606-10.
-
2002: Okamoto Tamami; Yamagishi Sho-ichi; Inagaki Yosuke; Amano Shinjiro; Takeuchi Masayoshi; Kikuchi Seiji; Ohno Shigeaki; Yoshimura Akihiko
Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro.
Biochemical and biophysical research communications 2002;297(2):419-24.
-
2002: Yamagishi Sho-ichi; Inagaki Yosuke; Amano Shinjiro; Okamoto Tamami; Takeuchi Masayoshi; Makita Zenji
Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties.
Biochemical and biophysical research communications 2002;296(4):877-82.
-
2002: Sasaki Nobuyuki; Takeuchi Masayoshi; Chowei Hiroshi; Kikuchi Seiji; Hayashi Yorihide; Nakano Norihito; Ikeda Hiroshi; Yamagishi Sho-ichi; Kitamoto Tetsuyuki; Saito Toshikazu; Makita Zenji
Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.
Neuroscience letters 2002;326(2):117-20.
-
2002: Yamagishi Sho-ichi; Inagaki Yosuke; Okamoto Tamami; Amano Shinjiro; Koga Kohachiro; Takeuchi Masayoshi; Makita Zenji
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells.
The Journal of biological chemistry 2002;277(23):20309-15.
-
2002: Yamagishi Sho-Ichi; Okamoto Tamami; Amano Shinjiro; Inagaki Yosuke; Koga Kohachiro; Koga Mari; Choei Hiroshi; Sasaki Nobuyuki; Kikuchi Seiji; Takeuchi Masayoshi; Makita Zenji
Palmitate-induced apoptosis of microvascular endothelial cells and pericytes.
Molecular medicine (Cambridge, Mass.) 2002;8(4):179-84.
-
2002: Yamagishi Sho-ichi; Amano Shinjiro; Inagaki Yosuke; Okamoto Tamami; Koga Kohachiro; Sasaki Nobuyuki; Yamamoto Hiroshi; Takeuchi Masayoshi; Makita Zenji
Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes.
Biochemical and biophysical research communications 2002;290(3):973-8.
-
2002: Yamagishi S; Amano S; Inagaki Y; Okamoto T; Koda Y; Soejima M; Kimura H
Pigment epithelium-derived factor Met72Thr polymorphism in patients with diabetic microangiopathy.
International journal of clinical pharmacology research 2002;22(3-4):67-71.
-
2002: Yamagishi S; Inagaki Y; Amano S; Okamoto T; Takeuchi M
Up-regulation of vascular endothelial growth factor and down-regulation of pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes.
International journal of tissue reactions 2002;24(4):137-42.
-
2002: Yamagishi S; Koga K; Inagaki Y; Amano S; Okamoto T; Takeuchi M
Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Drugs under experimental and clinical research 2002;28(6):221-7.
-
2002: Koga K; Yamagishi S; Okamoto T; Inagaki Y; Amano S; Takeuchi M; Makita Z
Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction.
International journal of clinical pharmacology research 2002;22(1):13-7.
-
2001: Yamagishi S; Takeuchi M; Makita Z
Advanced glycation end products and the pathogenesis of diabetic nephropathy.
Contributions to nephrology 2001;(134):30-5.
Sign-in to see more
